ASCO Annual Meeting

Enhertu Is Promising for Difficult-to-Treat Solid Cancers

June 6th 2023, 7:00pm

Adding Jemperli to Chemo Lengthens Time to Progression in Early Endometrial Cancer

June 6th 2023, 3:00pm

Jemperli plus carboplatin and paclitaxel also helped patients with early endometrial cancer maintain their health-related quality of life throughout follow-up.

HER3-Directed Therapy Was Effective and Safe in Breast Cancer Subtype

June 6th 2023, 1:00pm

Patients with ER-positive, triple-negative metastatic breast cancer treated with a HER3-direct antibody drug conjugate obtained clinical responses with a positive safety profile.

Survival Benefit With Lenvima/Keytruda for Advanced Clear Cell RCC Continues After 4 Years

June 5th 2023, 10:00pm

After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.

Lenvima Plus Keytruda ‘Stood the Test of Time’ for Kidney Cancer

June 5th 2023, 9:00pm

Longer follow-up data showed that Lenvima plus Keytruda still outperformed Sutent in the treatment of patients with advanced renal cell carcinoma.

Presurgical FOLFOX/Chemo as Effective as Chemoradiation in Rectal Cancer

June 5th 2023, 8:00pm

Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation.

Triplet Regimen Bests Single-Agent Cabometyx in Soft Tissue Sarcoma

June 5th 2023, 7:00pm

Adding Opdivo and Yervoy to Cabometyx led to improved progression-free survival and disease control rates in patients with soft tissue sarcoma, recent research showed.

Vorasidenib May ‘Change the Treatment Paradigm’ for Low-Grade Glioma

June 5th 2023, 2:00pm

Vorasidenib reduced the risk of disease progression or death for certain patients with low-grade brain cancer, recent study results showed.

Side Effects Manageable From Talzenna/Xtandi Treatment in Prostate Cancer Subset

June 5th 2023, 1:00pm

Side effects such as anemia and other blood-related events were resolved with dose reductions and/or supportive care in men with metastatic castration-resistant prostate cancer.

Elranatamab Elicits Early, Deep Responses in Relapsed/Refractory Myeloma

June 4th 2023, 9:00pm

Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.